1. Academic Validation
  2. Structural insight into selectivity of amylin and calcitonin receptor agonists

Structural insight into selectivity of amylin and calcitonin receptor agonists

  • Nat Chem Biol. 2024 Feb;20(2):162-169. doi: 10.1038/s41589-023-01393-4.
Jianjun Cao 1 2 Matthew J Belousoff 1 2 Elliot Gerrard 1 2 Radostin Danev 3 Madeleine M Fletcher 1 4 Emma Dal Maso 1 2 Herman Schreuder 5 Katrin Lorenz 5 Andreas Evers 5 6 Garima Tiwari 5 7 Melissa Besenius 5 Ziyu Li 5 Rachel M Johnson 1 2 8 Denise Wootten 9 10 Patrick M Sexton 11 12
Affiliations

Affiliations

  • 1 Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • 2 ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • 3 Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
  • 4 GlaxoSmithKline, Abbotsford, Victoria, Australia.
  • 5 Sanofi-Aventis Deutschland GmbH, R&D, Industriepark Hoechst, Frankfurt am Main, Germany.
  • 6 Merck Healthcare KGaA, Darmstadt, Germany.
  • 7 Janssen Vaccines and Prevention B.V., Leiden, the Netherlands.
  • 8 OMass Therapeutics, Oxford, UK.
  • 9 Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. [email protected].
  • 10 ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. [email protected].
  • 11 Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. [email protected].
  • 12 ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. [email protected].
Abstract

Amylin receptors (AMYRs), heterodimers of the Calcitonin receptor (CTR) and one of three receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR activation by Amy is the formation of a 'bypass' secondary structural motif (residues S19-P25). This study explored potential tuning of peptide selectivity through modification to residues 19-22, resulting in a selective AMYR agonist, San385, as well as nonselective dual amylin and Calcitonin receptor agonists (DACRAs), with San45 being an exemplar. We determined the structure and dynamics of San385-bound AMY3R, and San45 bound to AMY3R or CTR. San45, via its conjugated lipid at position 21, was anchored at the edge of the receptor bundle, enabling a stable, alternative binding mode when bound to the CTR, in addition to the bypass mode of binding to AMY3R. Targeted lipid modification may provide a single intervention strategy for design of long-acting, nonselective, Amy-based DACRAs with potential anti-obesity effects.

Figures
Products